199 related articles for article (PubMed ID: 34702753)
1. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.
Walti CS; Loes AN; Shuey K; Krantz EM; Boonyaratanakornkit J; Keane-Candib J; Loeffelholz T; Wolf CR; Taylor JJ; Gardner RA; Green DJ; Cowan AJ; Maloney DG; Turtle CJ; Pergam SA; Chu HY; Bloom JD; Hill JA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702753
[TBL] [Abstract][Full Text] [Related]
2. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy.
Walti CS; Loes AN; Shuey K; Krantz EM; Boonyaratanakornkit J; Keane-Candib J; Loeffelholz T; Wolf CR; Taylor JJ; Gardner RA; Green DJ; Cowan AJ; Maloney DG; Turtle CJ; Pergam SA; Chu HY; Bloom JD; Hill JA
medRxiv; 2021 May; ():. PubMed ID: 34013294
[TBL] [Abstract][Full Text] [Related]
3. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
[TBL] [Abstract][Full Text] [Related]
5. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
Front Immunol; 2018; 9():3103. PubMed ID: 30761157
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
9. Long-term seroprotective response of trivalent seasonal influenza vaccine in HIV-infected children, regardless of immunogenicity before immunisation.
Moolasart V; Manosuthi W; Ausavapipit J; Chottanapund S; Likanonsakul S; Uttayamakul S; Srisopha S; Lerdsamran H; Puthavathana P
Int J STD AIDS; 2016 Aug; 27(9):761-8. PubMed ID: 26138900
[TBL] [Abstract][Full Text] [Related]
10. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Meir J; Abid MA; Abid MB
Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
[TBL] [Abstract][Full Text] [Related]
13. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
14. HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.
Gilbert PB; Fong Y; Juraska M; Carpp LN; Monto AS; Martin ET; Petrie JG
BMC Infect Dis; 2019 May; 19(1):453. PubMed ID: 31117986
[TBL] [Abstract][Full Text] [Related]
15. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
16. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.
Dhédin N; Krivine A; Le Corre N; Mallet A; Lioure B; Bay JO; Rubio MT; Agape P; Thiébaut A; Le Goff J; Autran B; Ribaud P
Vaccine; 2014 Jan; 32(5):585-91. PubMed ID: 24333120
[TBL] [Abstract][Full Text] [Related]
17. Hemagglutinin-specific CD4
Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
Montalban C; Montellano MB; Santos J; Lavis N
Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
[TBL] [Abstract][Full Text] [Related]
19. Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan.
Mondini G; Braga PE; Lopes MH; Sartori AMC; Miyaji KT; Infante V; Randi BA; Timenetsky MDCST; Ferreira JCOA; Sakita NK; Precioso AR
Rev Inst Med Trop Sao Paulo; 2018 Jul; 60():e37. PubMed ID: 30066805
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
